Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exploratory phase II study in patients after treatment of high grade brain tumors to assess the technical performance of Tc-99m tetrofosmin for differentiation of recurrence versus radiation necrosis

Next Previous
X
Search
Trial Profile

Exploratory phase II study in patients after treatment of high grade brain tumors to assess the technical performance of Tc-99m tetrofosmin for differentiation of recurrence versus radiation necrosis

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 31 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Technetium 99m tetrofosmin (Primary)
  • Indications Brain cancer
  • Focus Diagnostic use
  • Acronyms GLIOMARK1

    • Most Recent Events

    • 22 Feb 2018 This trial has been completed in Hungary as per European Clinical Trials Database record.
    • 16 Jul 2017 Planned number of patients changed from 30 to 51.
    • 06 Feb 2017 This trial has been completed in Germany, according to European Clinical Trials Database.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top